Introduction
COPD is a chronic disorder characterized by fixed airway obstruction with accompanying respiratory symptoms such as persistent and progressive breathlessness, chronic productive cough and limited exercise capacity. It is predominantly caused by smoking; however, other factors, particularly occupational exposures, may also contribute to the development of COPD. The impairment of lung function is usually progressive and is not fully reversible. Exacerbations often occur, where there is a rapid and sustained worsening of symptoms beyond normal day-to-day variations. COPD is a global health problem that causes substantial morbidity and mortality. It is the fourth leading cause of death worldwide. 1 Current disease management guidelines developed by GOLD recommend maintenance therapy with either a longacting muscarinic antagonist (LAMA) or a long-acting beta agonist (LABA) in patients with moderate or severe COPD (Groups B-D) when short-acting muscarinic antagonists (SAMAs) fail to control symptoms and exacerbation rates. 2 Patients who have persistent symptoms or exacerbations should be treated with a combination of LAMA and LABA (LAMA/LABA) or inhaled corticosteroids (ICS) and LABA (ICS/LABA). To our knowledge, there is no published systematic review that compares all treatment options. The aim of this network meta-analysis was to comprehensively compare the efficacy and safety of the individual agents under the various therapeutic classes of inhalers commonly used in the treatment of COPD, namely SAMAs, LAMAs, LAMA/LABA fixed-dose combinations (FDCs) and ICS/ LABA FDCs. LABA monotherapy was not included in this analysis as it is infrequently used compared to the other classes of inhalers in Singapore.
Materials and methods
This review followed the PRISMA guidelines.
Search strategy
A systematic search of PubMed and Embase was conducted up to 15 November 2017. The search strategy employed a combination of medical subject headings and text words related to the drug classes of interest, the term "COPD" and their synonyms (Table S1 ). Reference lists from published systematic reviews were hand-searched for additional publications. The searches were limited to English language.
Study selection
Randomized, parallel-group, controlled design studies of 12 weeks' duration, which compared LAMA/LABA FDCs (aclidinium/formoterol 400/12 mcg twice a day [AclForm] , indacaterol/glycopyrronium 110/50 mcg once a day [IndaGlyco] , tiotropium/olodaterol 5/5 mcg once a day [TioOlo] [FFVI] , budesonide/formoterol 320/9 mcg twice a day [BudeForm] ) and SAMA (ipratropium 40 mcg four times a day [Ipra] ) with each other or with placebo were selected if they included adults with stable, moderate-to-very severe COPD. The eligible study treatments were restricted to all combinations at their licensed doses which were available at the time of review. Studies were required to report at least one of the following clinical and health status endpoints: trough FEV 1 , transitional dyspnea index (TDI), St George's Respiratory Questionnaire (SGRQ) and safety (frequency of adverse events [AEs] ). There was considerable heterogeneity in the definition of exacerbation outcomes across the studies, which limited their ability to be pooled in a network. Most of the earlier studies defined exacerbation by the symptoms (eg, at least 3 days of increased sputum production), while more recent studies defined exacerbation by the treatment received (eg, requiring corticosteroids or hospital admission).
Data extraction and risk of bias assessment
Two authors (MIAA and LET) independently reviewed the search results and assessed the eligibility of the studies for selection. Any disagreements were resolved by discussion to achieve consensus. The data extraction was performed independently using a standard template and checked for discrepancies. Specific data points of interest that were only presented in graphs were extracted using WebPlotDigitizer. comparator, provided that the studies included are comparable in terms of treatment effect modifiers. The synthesis of direct and indirect evidence produces a more precise and refined estimate of treatment effectiveness by maximizing the use of available data for all treatments within the network. Direct pairwise comparisons were also conducted using the metan package in Stata. 6 The primary outcome was trough FEV 1 (in mL); secondary outcomes included were TDI, SGRQ and AEs. For the continuous outcomes (FEV 1 , SGRQ and TDI), the mean difference (MD) in the change from baseline values between the two arms was used in the analyses. The minimal clinically important difference (MCID) for FEV 1 is 100 mL. 7, 8 The proportions of patients who attained the MCID in TDI (TDI responders, a 1 unit increase in TDI) 9 and SGRQ (SGRQ responders, a 4 unit decrease in SGRQ score) 10 were also analyzed. Observation time points of 12 and 24 weeks were chosen as they were the two consistently reported time points across the studies. A result was considered significant if the 95% CI did not include 0 or one for the continuous and dichotomous outcomes, respectively. The Surface Under the Cumulative RAnking (SUCRA) curve was obtained to determine the relative probability of a treatment being the best option for each outcome measure.
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Possible network inconsistency was assessed using the design-by-treatment model approach described by White. 5 This approach provided a global test for inconsistency, with a P-value 0.05 indicating violation of the consistency assumption in the network.
Results

Search and selection results
The electronic database search identified 1,611 citations, of which 1,485 were excluded on abstract review ( Figure S1 ). A further 50 were excluded after reviewing the full-text articles, leaving 74 studies reported by 75 articles included in the final selection.
The 74 studies selected for inclusion were published between 2000 and 2017. The study characteristics are presented in Table 1 . Thirty-nine studies (53%) were placebo controlled and 35 were active controlled. Overall, there were more published studies for tiotropium 18 mcg compared to the other agents, given it was the first LAMA licensed for COPD. Most studies (67 studies; 91%) had large sample sizes with 200 participants. All studies included patients aged at least 35 years, with a smoking history of at least 10 packs per year. Six studies only included patients with a prior history of exacerbations, while five studies only included patients without Figure 1 . A total of 74,832 patients were included in the 74 studies. The key patient characteristics and assessment of risk of bias for each study are presented in Table 2 . Mean ages ranged from 61 to 73 years; proportion of males and current smokers ranged from 48% to 99% and from 22% to 88%, respectively. The mean FEV 1 predicted at baseline ranged from 35% to 78%. Majority of the studies were assessed to have low or unclear risk of bias. Inconsistency models were not significant for all outcomes, implying that the consistency assumption was not violated.
Efficacy
Trough FEV 1 change from baseline Trough FEV 1 results were reported in 59 studies at week 12 and in 39 studies at week 24. All LAMAs, LAMA/LABAs and ICS/LABAs led to significantly greater improvement in trough FEV 1 compared to SAMA and placebo at weeks 12 and 24 (Tables 3 and 4 ). While some of the comparisons among LAMAs, LAMA/LABAs and ICS/LABAs showed statistical significance, the results were generally not clinically significant with respect to an MCID of 100 mL. For example, among the LAMAs, Umec led to statistically significant improvement in trough FEV 1 at week 12 compared to Tio18 (mean difference [MD] of 37 mL, 95% CI 13-62 mL) and Glyco (MD 31 mL, 95% CI 6-57 mL). However, there were no significant differences in trough FEV 1 for all LAMA vs LAMA comparisons at week 24. Among the LAMA/LABAs, there were no significant differences between IndaGlyco, TioOlo and UmecVil at weeks 12 and 24. IndaGlyco and UmecVil showed statistically significant improvement in FEV 1 when compared to AclForm at both weeks 12 and 24. The MDs ranged from 43 to 59 mL (point estimates). Statistically significant improvement at weeks 12 and 24 was also seen for IndaGlyco, TioOlo and UmecVil compared to all LAMAs. The MDs ranged from 48 to 88 mL (point estimates). On the other hand, AclForm exhibited no significant difference compared to any LAMAs. Among the ICS/LABAs, the results were mixed with some showing significant differences between the agents (FFVI vs SFC250 at week 12, MD 40 mL; FFVI vs BudeForm at week 24, MD 58 mL; BudeForm vs SFC250 at week 24, MD −82 mL). When compared to the LAMAs, ICS/LABAs had a similar effect on FEV 1 at week 12, except SFC250 vs Umec (MD −52 mL, 95% CI −85 to −18 mL, favoring Umec) and FFVI vs Tio18 (MD 25 mL, 95% CI 4-47 mL, favoring FFVI). At week 24, ICS/LABAs were generally comparable to the LAMAs, except BudeForm vs Glyco (MD −40 mL, 95% CI −77 to 3 mL, favoring Glyco) and Tio18 (MD −35 mL, 95% CI −69 
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Notes: Comparisons between treatments should be read from left to right. The MD in milliliters with 95% CI are shown in the cell. MD 0
favors the column-defining treatment (lower triangle) and the row-defining treatment (upper triangle). Statistically significant results in bold. The lower triangle refers to the area below the colored boxes, correspondingly the upper triangle is the area above the colored boxes. Abbreviations: Acl, aclidinium; AclForm, aclidinium/formoterol; FFVI, fluticasone/vilanterol; Glyco, glycopyrronium; IndaGlyco, indacaterol/glycopyrronium; Ipra, ipratropium; MD, mean difference; NA, results not available; NMA, network meta-analysis; SFC250, fluticasone/salmeterol 250/50 mcg; SFC500, fluticasone/salmeterol 500/50 mcg; Tio5, tiotropium 5 mcg; Tio18, tiotropium 18 mcg; TioOlo, tiotropium/olodaterol; Umec, umeclidinium; UmecVil, umeclidinium/vilanterol. (Tables S2 and S3 ). There were no significant differences between the LAMA/LABAs except UmecVil vs TioOlo at week 12 (MD −0.51, 95% CI −0.94 to −0.07, favoring TioOlo). The difference was not considered to be clinically significant (MCID 1 point increase). There were no significant differences in TDI scores between all LAMA-LAMA comparisons at weeks 12 and 24. There were, however, some statistically significant improvements in TDI scores for LAMA/LABAs compared to LAMAs. Nonetheless, the magnitudes of difference in TDI scores were all lower than the MCID of 1 unit for these comparisons. Similarly, there were some statistically significant (but not clinically significant) differences when LAMA/LABAs were compared to ICS/LABAs. There were no significant differences in TDI scores when LAMAs were compared to ICS/ LABAs at both time points.
In terms of the proportion of TDI score responders (who achieved a minimum of 1-point improvement in TDI score), results were reported in 15 studies at week 12 and in 16 studies at week 24. Study participants treated with LAMAs, LAMA/LABAs or ICS/LABAs were more likely to achieve improvement in TDI score than those receiving placebo or SAMA (Tables S4 and S5 ). There was some evidence to show that LAMA/LABA treatment had higher odds of achieving TDI score improvement compared to LAMAs (UmecVil vs Tio18 at week 12: OR 1.49, 95% CI 1.16-1.93; IndaGlyco vs Tio18 at week 24: OR 1.45, 95% CI 1.11-1.89; AclForm vs Tio18 at week 24: OR 1.37, 95% CI 1.04-1.80). There were no significant differences in TDI score improvement when ICS/LABAs were compared with LAMAs or LAMA/ LABAs.
St George's Respiratory Questionnaire
Health-related quality-of-life (HRQoL) benefits as measured by SGRQ scores were reported in 34 studies at week 12 and in 29 studies at week 24. All LAMAs, LAMA/LABAs and ICS/LABAs showed statistically significant improvement in SGRQ score compared to placebo at week 12; however, the point estimates did not achieve clinical significance (MCID 4-point decrease) for SFC250, Acl, Glyco, Tio5 and Tio18 (Table S6) . At week 24, only some of the LAMAs and LAMA/LABAs showed statistically significant improvements in HRQoL vs placebo (Table S7 ), but none of the results reached clinical significance. A similar trend was seen when LAMAs, LAMA/LABAs and ICS/LABAs were compared to SAMA. Within each class, the LAMAs, LAMA/ LABAs and ICS/LABAs led to similar HRQoL improvements at weeks 12 and 24. While there were some statistically significant differences between LAMA/LABAs and LAMAs, these differences were not clinically significant.
In terms of the proportion of SGRQ score responders (achieving at least a 4-point reduction in SGRQ), results were reported in 21 studies at week 12 and in 19 studies at week 24. At both time points, all LAMAs, LAMA/LABAs and ICS/LABAs led to a significantly higher proportion of study participants achieving an improvement in SGRQ score compared to placebo (Tables S8 and S9 ). Relative to SAMA, only IndaGlyco and TioOlo showed a statistically significant difference in SGRQ responders at week 12 (Ipra vs IndaGlyco: OR 0.61, 95% CI 0.40-0.94; Ipra vs TioOlo: OR 0.53, 95% CI 0.33-0.85). There were no significant differences within the LAMA, LAMA/LABA and ICS/LABA classes at weeks 12 and 24 for SGRQ responders; however, some evidence was available to suggest that the LAMA/ LABAs led to a higher proportion of SGRQ responder compared to the LAMAs at both weeks 12 and 24.
Adverse events
Incidences of AEs were reported in 17 studies at week 12 and in 27 studies at week 24. There were no significant differences in the proportion of patients who experienced AEs for any comparison at week 12 (Table S10) . At week 24, a significantly higher proportion of patients receiving SFC500 had AEs compared to those receiving IndaGlyco (SFC500 vs IndaGlyco: OR 1.34, 95% CI 1.04-1.72; Table S11 ). This translated to a Number Needed to Harm of 14. No other significant differences with respect to AEs were found in other comparisons.
Ranking of treatments
In general, the LAMA/LABAs ranked the highest among the different drug classes for lung function improvement ( 
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Comparative efficacy of inhaled medications for COPD ranged from 64.5% to 97.6% (Table 5 ). The trend remained constant for all outcomes, with LAMA/LABAs having the highest SUCRA scores.
Discussion
Our network meta-analysis is the first to utilize a frequentist framework to comprehensively compare the effectiveness of SAMAs, LAMAs, LAMA/LABAs and ICS/LABAs using published randomized controlled studies. A frequentist framework allowed us to make statistical inference/comparisons based on significance testing using P-values. With regards to lung function, our results showed that LAMAs, LAMA/ LABAs and ICS/LABAs led to a greater improvement in trough FEV 1 compared with placebo and SAMA monotherapy. All LAMA/LABAs except aclidinium/formoterol were significantly better than LAMA monotherapy in improving lung function. Limited evidence also suggested LAMA/ LABAs led to greater improvements than ICS/LABAs. Of note, there was markedly more evidence available for lung function than other patient-relevant outcomes. Similar trends were, nonetheless, observed with respect to improvements in TDI and SGRQ scores, although not all results were statistically significant. Improvements with FEV 1 have been correlated with improvements in quality of life as demonstrated in previous analyses. 12 A recent study by Sion et al (2017) reported similar findings that LAMA/LABAs combinations were better than Tio alone or placebo. 88 Our results did not show any clinically significant differences among the different LAMAs and LAMA/LABAs within their classes, for all outcomes. These results were congruent with other published network meta-analyses which compared outcomes within the drug classes. Cope et al, 89 Karabis et al 90 and Ismaila et al 91 evaluated the comparative efficacy among the LAMA agents through a Bayesian framework and found no differences among them. Similarly, Schlueter et al 92 and Huisman et al 93 evaluated the comparative efficacy among LAMA/LABAs using the Bayesian approach and found no differences among all agents. Our analysis, which employs a frequentist framework and uses a network with more comprehensive treatment options (SAMA, LAMA, LAMA/LABA and ICS/LABA) for stable COPD, adds further confidence to these findings and expands the existing evidence base.
In considering the results, we need to be mindful of the limitations of the analysis. FEV 1 is the only outcome that is consistently reported across the trials. Given TDI and SGRQ outcomes can be reported as either total score or proportion of responders, this resulted in many studies not reporting both types of outcome. Therefore, there was uncertainty in our analysis of TDI and SGRQ outcomes, with the results reflected in wide CIs. , and hence were associated with a high risk of bias in terms of lack of blinding. Incomplete outcome data in some studies also may have increased uncertainty around some results. Small study bias was considered unlikely, given that most included trials had a sample size of at least 100 patients and each arm of all included comparisons had at least 50 patients. Most of the included studies were of a short duration with only 16 studies, out of the 74, reporting outcomes beyond the 24-week time point. Therefore, only the 12-and 24-week time points were selected for evaluation.
When performing network meta-analysis, patients from all pair-wise meta-analysis have not been randomized to different trials and randomization would, therefore, not hold across the set of trials used for the analysis. Thus, it is important to assess imbalance in patient characteristics and effect modifiers across trials to determine the face validity of the analysis. To ensure the assumptions of homogeneity and transitivity are met, the distribution of potential effect modifiers, such as gender distribution, mean age, and proportion of smokers, was assessed and found to be similar across the direct comparisons in the network. However, other effect modifiers, including mean COPD duration and proportion with exacerbation history, were not reported in the majority of the trials, which limited our ability to determine if our assumptions were met with respect to these characteristics. However, despite this limitation, it is unlikely that our results would be substantially biased given the consistency of results demonstrated between the network and direct comparison meta-analyses.
To address the potential influence of certain treatment effect modifiers, network meta-regression would have been appropriate to explore the impact of covariates on all of the data and allow for the simultaneous consideration of continuous and categorical covariates. However, we did not perform a meta-regression mainly due to the fact that the variation in FEV 1 was too small, and also due to the limited number of studies available in parts of the network. Model diagnostics and adequacy are difficult to assess. Even if the network meta-regression was performed, individual patient data would be necessary to avoid ecological bias and to gain greater statistical power to detect differences in treatment effects between the effect modifiers.
It is worth noting that although we have reported the ranking of all treatments using SUCRA curves, large differences in ranking probabilities between two treatments do not necessarily mean significant difference in relative treatment effect. To achieve a more objective assessment, the magnitude of absolute benefit should be accompanied with ranking information in order to minimize potential biased interpretation. Finally, our approach was based on individual treatments (eg, Acl, Glyco, Tio18, Tio5, Umec) instead of drug classes (eg, LAMAs) as it facilitated comparisons both within and across classes. However, this led to multiple comparisons involving all treatments from each class and, thus, difficulty in drawing conclusions at a therapeutic class level. The number of studies available for each individual treatment was also small, which may have resulted in low statistical power.
Conclusion
LAMA/LABA showed greatest improvement in lung function at weeks 12 and 24 compared with the other inhaled drug classes, while SAMA showed the least improvement. There were no significant differences among the LAMAs and LAMA/ LABAs within their respective classes. Results from our analysis may play a role in assisting clinicians make evidence-based treatment decisions and also in advising policymakers on the most effective treatments when making subsidy decisions. Other factors, including cost-effectiveness and patient preferences, may also be taken into account when determining the most optimal treatments for patients with stable COPD.
